id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1999-P-4073-0004,FDA,FDA-1999-P-4073,"Attachment C Side by Side Labeling Comparison of DARVOCET N-100 and Propoxyphene and Acetaminophen Tablets/Capsules 50mg/500mg re: Citizen Petition from Mikart, Inc.",Supporting & Related Material,Background Material,2017-07-25T04:00:00Z,2017,7,,,2017-07-25T14:23:41Z,,0,0,090000648295f33f
FDA-1999-P-4073-0007,FDA,FDA-1999-P-4073,"Petition Denial Response Letter from FDA CDER to Mikart, Inc.",Other,Denial of Petition,2017-07-25T04:00:00Z,2017,7,2017-07-25T04:00:00Z,,2017-07-25T14:34:07Z,,0,0,09000064804f5e6c
FDA-1999-P-4073-0005,FDA,FDA-1999-P-4073,"Acknowledgment Letter from FDA DDM to Mikart, Inc.",Other,Acknowledgement Letter/Receipt,2017-07-25T04:00:00Z,2017,7,2017-07-25T04:00:00Z,,2017-07-25T14:27:15Z,,0,0,09000064804f5e6a
FDA-1999-P-4073-0006,FDA,FDA-1999-P-4073,"Correction from Mikart, Inc.",Other,Correction(s),2017-07-25T04:00:00Z,2017,7,2017-07-25T04:00:00Z,,2017-07-25T14:30:54Z,,0,0,09000064804f5e6b
FDA-1999-P-4073-0002,FDA,FDA-1999-P-4073,"Attachment A Labeling for DARVOCET-N 100 re: Citizen Petition from Mikart, Inc.",Supporting & Related Material,Background Material,2017-07-25T04:00:00Z,2017,7,,,2017-07-25T14:21:22Z,,0,0,090000648295f33d
FDA-1999-P-4073-0003,FDA,FDA-1999-P-4073,"Attachment B Proposed Labeling for Propoxyphene Napsylate and Acetaminophen Tablets/Capsules 50mg/500mg re: Citizen Petition from Mikart, Inc.",Supporting & Related Material,Background Material,2017-07-25T04:00:00Z,2017,7,,,2017-07-25T14:21:07Z,,0,0,090000648295f33e
FDA-1999-P-4073-0001,FDA,FDA-1999-P-4073,"Citizen Petition from Mikart, Inc.",Other,Citizen Petition,2017-07-24T04:00:00Z,2017,7,1999-10-26T04:00:00Z,,2017-07-24T18:40:43Z,,0,0,09000064804f5e69